According to Mark Cuban on Twitter, Cost Plus Drugs has announced partnerships with several transparent, pass-through pharmacy benefit managers (PBMs), encouraging decision-makers to consult these PBMs before finalizing any corporate pharmacy benefits (Source: @mcuban, May 6, 2025). For investors and trading professionals in the healthcare and pharmaceutical sectors, this move signals a shift towards greater price transparency and potentially lower drug costs, which could impact the stock performance of traditional PBMs and benefit transparency-focused companies.